دورية أكاديمية
أعرض في EDS

NK cell heparanase controls tumor invasion and immune surveillance.

التفاصيل البيبلوغرافية
العنوان: NK cell heparanase controls tumor invasion and immune surveillance.
المؤلفون: Putz EM; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Mayfosh AJ; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia., Kos K; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Barkauskas DS; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Nakamura K; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Town L; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia., Goodall KJ; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia., Yee DY; John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory, Australia., Poon IK; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia., Baschuk N; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia., Souza-Fonseca-Guimaraes F; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.; School of Medicine, The University of Queensland, Herston, Queensland, Australia.; Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia., Hulett MD; Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Victoria, Australia., Smyth MJ; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.; School of Medicine, The University of Queensland, Herston, Queensland, Australia.
المصدر: The Journal of clinical investigation [J Clin Invest] 2017 Jun 30; Vol. 127 (7), pp. 2777-2788. Date of Electronic Publication: 2017 Jun 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.
مواضيع طبية MeSH: Immunologic Surveillance*, Heparin Lyase/*immunology , Killer Cells, Natural/*immunology , Neoplasms, Experimental/*immunology, Animals ; Cell Line, Tumor ; Cytokines/genetics ; Cytokines/immunology ; Female ; Heparin Lyase/genetics ; Humans ; Killer Cells, Natural/pathology ; Male ; Mice ; Mice, Knockout ; NK Cell Lectin-Like Receptor Subfamily K/genetics ; NK Cell Lectin-Like Receptor Subfamily K/immunology ; Neoplasm Invasiveness/genetics ; Neoplasm Invasiveness/immunology ; Neoplasm Metastasis ; Neoplasms, Experimental/genetics ; Neoplasms, Experimental/pathology ; Nuclear Matrix-Associated Proteins/genetics ; Nuclear Matrix-Associated Proteins/immunology ; Nucleocytoplasmic Transport Proteins/genetics ; Nucleocytoplasmic Transport Proteins/immunology
مستخلص: NK cells are highly efficient at preventing cancer metastasis but are infrequently found in the core of primary tumors. Here, have we demonstrated that freshly isolated mouse and human NK cells express low levels of the endo-β-D-glucuronidase heparanase that increase upon NK cell activation. Heparanase deficiency did not affect development, differentiation, or tissue localization of NK cells under steady-state conditions. However, mice lacking heparanase specifically in NK cells (Hpsefl/fl NKp46-iCre mice) were highly tumor prone when challenged with the carcinogen methylcholanthrene (MCA). Hpsefl/fl NKp46-iCre mice were also more susceptible to tumor growth than were their littermate controls when challenged with the established mouse lymphoma cell line RMA-S-RAE-1β, which overexpresses the NK cell group 2D (NKG2D) ligand RAE-1β, or when inoculated with metastatic melanoma, prostate carcinoma, or mammary carcinoma cell lines. NK cell invasion of primary tumors and recruitment to the site of metastasis were strictly dependent on the presence of heparanase. Cytokine and immune checkpoint blockade immunotherapy for metastases was compromised when NK cells lacked heparanase. Our data suggest that heparanase plays a critical role in NK cell invasion into tumors and thereby tumor progression and metastases. This should be considered when systemically treating cancer patients with heparanase inhibitors, since the potential adverse effect on NK cell infiltration might limit the antitumor activity of the inhibitors.
References: Nat Immunol. 2016 Aug 19;17 (9):1025-36. (PMID: 27540992)
Future Med Chem. 2016 Apr;8(6):647-80. (PMID: 27057774)
J Biomed Biotechnol. 2011;2011:676198. (PMID: 21541191)
Biochem J. 1997 Jul 1;325 ( Pt 1):229-37. (PMID: 9224651)
FASEB J. 2003 Jun;17 (9):1015-25. (PMID: 12773484)
J Immunol Methods. 2003 Sep;280(1-2):135-8. (PMID: 12972194)
J Clin Invest. 2016 Jan;126(1):207-19. (PMID: 26649979)
Clin Cancer Res. 2011 Feb 15;17(4):678-89. (PMID: 21325295)
J Exp Med. 1995 May 1;181(5):1929-34. (PMID: 7722469)
Cancer Res. 2008 Oct 15;68(20):8437-45. (PMID: 18922917)
Br J Cancer. 2011 Feb 15;104(4):635-42. (PMID: 21285983)
Nat Med. 1999 Jul;5(7):803-9. (PMID: 10395326)
PLoS One. 2009;4(4):e5181. (PMID: 19360105)
Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):377-81. (PMID: 7831294)
J Immunol. 2006 Jun 1;176(11):6417-24. (PMID: 16709798)
Int Immunol. 1994 Apr;6(4):507-13. (PMID: 8018592)
J Exp Med. 2002 Jun 3;195(11):1479-90. (PMID: 12045246)
Matrix Biol. 2013 Jun 24;32(5):234-40. (PMID: 23499528)
Cancer Discov. 2016 Dec;6(12 ):1382-1399. (PMID: 27663893)
Int Immunol. 2001 Apr;13(4):459-63. (PMID: 11282985)
Trends Biochem Sci. 2009 Oct;34(10):511-9. (PMID: 19733083)
Eur J Immunol. 2014 Apr;44(4):1016-30. (PMID: 24532362)
J Biol Chem. 2004 May 28;279(22):23536-41. (PMID: 15044433)
J Immunol Res. 2016;2016:4684268. (PMID: 27294158)
Methods Mol Biol. 2010;612:27-38. (PMID: 20033632)
Cancer Immunol Immunother. 2015 Feb;64(2):225-35. (PMID: 25344904)
Cell. 1992 Mar 6;68(5):855-67. (PMID: 1547487)
Oncoimmunology. 2015 Apr 1;4(4):e998119. (PMID: 26137412)
Cold Spring Harb Perspect Biol. 2011 Jul 01;3(7):null. (PMID: 21690215)
Front Oncol. 2014 Jul 24;4:195. (PMID: 25105093)
PLoS One. 2015 Jun 03;10(6):e0127032. (PMID: 26039697)
J Leukoc Biol. 2014 Apr;95(4):677-88. (PMID: 24319286)
Cancer Res. 2009 Mar 1;69(5):1758-67. (PMID: 19244131)
Cancer Discov. 2014 May;4(5):522-6. (PMID: 24795012)
Cancer. 1997 Jun 15;79(12):2320-8. (PMID: 9191519)
Curr Opin Virol. 2015 Dec;15:9-18. (PMID: 26208082)
Nat Med. 1999 Jul;5(7):793-802. (PMID: 10395325)
J Immunol. 2002 Nov 15;169(10):5377-81. (PMID: 12421908)
FASEB J. 2015 May;29(5):2010-21. (PMID: 25634957)
Transcription. 2012 May-Jun;3(3):130-45. (PMID: 22771948)
Cancer Res. 2014 Dec 15;74(24):7298-308. (PMID: 25351955)
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7808-E7817. (PMID: 27849593)
J Biol Chem. 2013 Apr 26;288(17 ):12366-75. (PMID: 23504323)
Nature. 2001 Sep 13;413(6852):165-71. (PMID: 11557981)
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18324-9. (PMID: 22021440)
Oncotarget. 2016 Jun 28;7(26):39486-39496. (PMID: 27129145)
J Biol Chem. 2008 Jun 27;283(26):18167-76. (PMID: 18450756)
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):704-9. (PMID: 26729870)
Oncotarget. 2016 Jan 12;7(2):1598-607. (PMID: 26624982)
J Biol Chem. 2011 Sep 2;286(35):30377-83. (PMID: 21757697)
FEBS J. 2017 Jan;284(1):42-55. (PMID: 27758044)
Cancer Discov. 2016 Apr;6(4):446-59. (PMID: 26787820)
Matrix Biol. 2013 Jun 24;32(5):241-51. (PMID: 23499530)
Nat Rev Cancer. 2012 Mar 15;12 (4):298-306. (PMID: 22419253)
Int J Biochem Cell Biol. 2010 Sep;42(9):1507-16. (PMID: 20561914)
Cancer. 2000 Feb 1;88(3):577-83. (PMID: 10649250)
PLoS One. 2012;7(5):e35602. (PMID: 22590508)
Oncotarget. 2015 Jun 10;6(16):14360-73. (PMID: 25961317)
Biochim Biophys Acta. 2001 Mar 21;1471(3):M99-108. (PMID: 11250066)
J Biol Chem. 2003 Dec 12;278(50):50377-85. (PMID: 14522979)
PLoS One. 2014 Oct 08;9(10):e109596. (PMID: 25295599)
Matrix Biol. 2013 Jun 24;32(5):228-33. (PMID: 23499527)
Semin Immunol. 2014 Apr;26(2):152-60. (PMID: 24582551)
Nat Med. 2015 May;21(5):524-9. (PMID: 25849134)
Curr Protoc Cell Biol. 2001 May;Chapter 10:Unit 10.4. (PMID: 18228298)
معلومات مُعتمدة: EP-C-15-008 United States EPA EPA; J 3635 Austria FWF_ Austrian Science Fund FWF
المشرفين على المادة: 0 (Cytokines)
0 (KLRK1 protein, human)
0 (NK Cell Lectin-Like Receptor Subfamily K)
0 (Nuclear Matrix-Associated Proteins)
0 (Nucleocytoplasmic Transport Proteins)
0 (RAE1 protein, human)
EC 4.2.2.7 (Heparin Lyase)
تواريخ الأحداث: Date Created: 20170606 Date Completed: 20170914 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC5490772
DOI: 10.1172/JCI92958
PMID: 28581441
قاعدة البيانات: MEDLINE
الوصف
تدمد:1558-8238
DOI:10.1172/JCI92958